Clinical Trial Update: A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept clinical trial evaluating IBI3002 in moderate-to-severe Atopic dermatitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• IBI3002

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Atopic Dermatitis | Phase 2 | Status: RECRUITING